Author Archives: Lindsey Shapiro

Genetics not found to influence Cosentyx treatment responses

The responses to Cosentyx (secukinumab) among people with ankylosing spondylitis (AS) and other inflammatory diseases aren’t significantly impacted by a person’s genetic background, a recent study suggests. The findings challenge an existing hypothesis that the variable responses to the therapy in clinical practice could largely be driven by…

Contents of cell cargo carriers may offer insights into AS biomarkers

Exosomes, which are tiny carriers for cellular cargo, are found to have significantly different contents in ankylosing spondylitis (AS) patients compared with healthy people, which in turn has marked influences on immune cell function, according to a recent study. Researchers specifically identified that the profile of molecules called microRNAs…

Fatty lesions don’t explain new bone formation in AS: Study

The effects of inflammation on the later development of new bone outgrowths in certain parts of the spine in ankylosing spondylitis (AS) patients are largely not explained by the intermediate formation of fatty deposits, according to a new study. The findings, which take into account data from two clinical…

Potential AS genetic biomarkers identified in study

Genetic analyses revealed a number of genes with altered activity in ankylosing spondylitis (AS) patients compared with healthy people, which researchers believe could serve as novel disease biomarkers. Among them, the PPARG and MDM2 genes — both of which are involved in inflammation — were found to hold the…

Cosentyx shows safety, efficacy over 1 year in real-world AS study

One year of treatment with Cosentyx (secukinumab) showed safety and efficacy in a real-world study conducted in Italy, lowering disease activity among people with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Men were overall more likely than women to achieve disease remission after a year of treatment. “This…

Older AS patients may be at greater risk for some blood cancers

Ankylosing spondylitis (AS) patients 65 and older may be at an increased risk of certain blood cancers compared with older adults in the general population, according to a recent study. The risk for these cancers, however, was similar among AS patients and people with another inflammatory condition called inflammatory…

Plans Afoot to Create Algorithm That Predicts Treatment Responses

The biotech company Girihlet will collaborate with Mayo Clinic to develop an algorithm that evaluates the effects of immune-suppressing treatments in patients with ankylosing spondylitis (AS), Girihlet announced. Under the so-called “know-how agreement,” Girihlet will use its proprietary ImmuneScanner technology to monitor changes in immune T-cells…

Evidence for Most AS Blood Biomarkers Weak: Umbrella Review

Platelet counts and blood levels of inflammatory proteins interleukin-23 (IL-23) and interleukin-17 (IL-17) were identified as the strongest potential non-genetic biomarkers of ankylosing spondylitis (AS) in a recent umbrella review study. The study, which looked at 43 previously identified biomarkers, found the evidence was weak for most others. The…